173 related articles for article (PubMed ID: 38338310)
1. A High-Throughput NMR Method for Lipoprotein-X Quantification.
Garcia E; Shalaurova I; Matyus SP; Freeman LA; Neufeld EB; Sampson ML; Zubirán R; Wolska A; Remaley AT; Otvos JD; Connelly MA
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338310
[TBL] [Abstract][Full Text] [Related]
2. LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.
Amar MJA; Freeman LA; Nishida T; Sampson ML; Pryor M; Vaisman BL; Neufeld EB; Karathanasis SK; Remaley AT
Pharmacol Res Perspect; 2020 Feb; 8(1):e00554. PubMed ID: 31893124
[TBL] [Abstract][Full Text] [Related]
3. Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo.
Freeman LA; Shamburek RD; Sampson ML; Neufeld EB; Sato M; Karathanasis SK; Remaley AT
J Lipid Res; 2019 May; 60(5):1050-1057. PubMed ID: 30808683
[TBL] [Abstract][Full Text] [Related]
4. Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.
O K; Frohlich J
J Lipid Res; 1995 Nov; 36(11):2344-54. PubMed ID: 8656072
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
[TBL] [Abstract][Full Text] [Related]
6. Biochemistry and clinical relevance of lipoprotein X.
Narayanan S
Ann Clin Lab Sci; 1984; 14(5):371-4. PubMed ID: 6476782
[TBL] [Abstract][Full Text] [Related]
7. Dyslipoproteinaemia of liver disease.
Miller JP
Baillieres Clin Endocrinol Metab; 1990 Dec; 4(4):807-32. PubMed ID: 2082907
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-X fifty years after its original discovery.
Fellin R; Manzato E
Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-X.
Narayanan S
CRC Crit Rev Clin Lab Sci; 1979 Aug; 11(1):31-51. PubMed ID: 389551
[TBL] [Abstract][Full Text] [Related]
10. Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature.
Jung Y; Nelson HA; Lin DM
J Clin Apher; 2024 Feb; 39(1):e22105. PubMed ID: 38334173
[TBL] [Abstract][Full Text] [Related]
11. Controversy over the atherogenicity of lipoprotein-X.
Miida T; Hirayama S
Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):117-123. PubMed ID: 30694826
[TBL] [Abstract][Full Text] [Related]
12. [The significance of LP-X cholesterol in the differential diagnosis of cholestasis (author's transl)].
Wieland H; Meissner-Heins H; Heins C; Seidel D
Klin Wochenschr; 1982 Apr; 60(7):343-8. PubMed ID: 7078029
[TBL] [Abstract][Full Text] [Related]
13. Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy.
Yee MS; Pavitt DV; Richmond W; Cook HT; McLean AG; Valabhji J; Elkeles RS
Atherosclerosis; 2009 Aug; 205(2):528-32. PubMed ID: 19230892
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-X levels in extrahepatic versus intrahepatic cholestasis.
Simon JB; Poon RW
Gastroenterology; 1978 Aug; 75(2):177-80. PubMed ID: 208914
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein subfractions highly associated with renal damage in familial lecithin:cholesterol acyltransferase deficiency.
Kuroda M; Holleboom AG; Stroes ES; Asada S; Aoyagi Y; Kamata K; Yamashita S; Ishibashi S; Saito Y; Bujo H
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1756-62. PubMed ID: 24876348
[TBL] [Abstract][Full Text] [Related]
16. [Studies on the structure and metabolism of lipoprotein-X (LP-X), the abnormal plasmalipoprotein in cholestasis (author's transl)].
Seidel D
Klin Wochenschr; 1977 Jul; 55(13):611-23. PubMed ID: 197298
[TBL] [Abstract][Full Text] [Related]
17. Quantitative studies of lipoprotein-X in familial lecithin: cholesterol acyltransferase deficiency and during cholesterol esterification.
Ritland S; Gjone E
Clin Chim Acta; 1975 Mar; 59(2):109-19. PubMed ID: 1091378
[TBL] [Abstract][Full Text] [Related]
18. Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis.
Oldoni F; Baldassarre D; Castelnuovo S; Ossoli A; Amato M; van Capelleveen J; Hovingh GK; De Groot E; Bochem A; Simonelli S; Barbieri S; Veglia F; Franceschini G; Kuivenhoven JA; Holleboom AG; Calabresi L
Circulation; 2018 Sep; 138(10):1000-1007. PubMed ID: 29748187
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated acquired lecithin-cholesterol acyltransferase deficiency: A case report and literature review.
Ishibashi R; Takemoto M; Tsurutani Y; Kuroda M; Ogawa M; Wakabayashi H; Uesugi N; Nagata M; Imai N; Hattori A; Sakamoto K; Kitamoto T; Maezawa Y; Narita I; Hiroi S; Furuta A; Miida T; Yokote K
J Clin Lipidol; 2018; 12(4):888-897.e2. PubMed ID: 29937398
[TBL] [Abstract][Full Text] [Related]
20. Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.
Bedi S; Garcia E; Jeyarajah EJ; Shalaurova I; Perez-Matos MC; Jiang ZG; Dullaart RPF; Matyus SP; Kirk WJ; Otvos JD; Davidson WS; Connelly MA
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32927635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
